Emerging infectious diseases · 2023
Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jacob Rajesh Abraham, Zhang Ali, Ajoge Hannah O, D'Agostino Michael R, Nirmalarajah Kuganya, Shigayeva Altynay, Demian Wael L, Baker Sheridan J C, Derakhshani Hooman, Rossi Laura, Nasir Jalees A, Panousis Emily M, Draia Ahmed N, Vermeiren Christie, Gilchrist Jodi, Smieja Nicole, Bulir David, Smieja Marek, Surette Michael G, McArthur Andrew G, McGeer Allison J, Mubareka Samira, Banerjee Arinjay, Miller Matthew S, Mossman Karen
Аннотация
Isolating and characterizing emerging SARS-CoV-2 variants is key to understanding virus pathogenesis. In this study, we isolated samples of the SARS-CoV-2 R.1 lineage, categorized as a variant under monitoring by the World Health Organization, and evaluated their sensitivity to neutralizing antibodies and type I interferons. We used convalescent serum samples from persons in Canada infected either with ancestral virus (wave 1) or the B.1.1.7 (Alpha) variant of concern (wave 3) for testing neutralization sensitivity. The R.1 isolates were potently neutralized by both the wave 1 and wave 3 convalescent serum samples, unlike the B.1.351 (Beta) variant of concern. Of note, the R.1 variant was significantly more resistant to type I interferons (IFN-α/β) than was the ancestral isolate. Our study demonstrates that the R.1 variant retained sensitivity to neutralizing antibodies but evolved resistance to type I interferons. This critical driving force will influence the trajectory of the pandemic.